Autolus Therapeutics (NASDAQ:AUTL) Shares Down 5.2%

Autolus Therapeutics plc (NASDAQ:AUTL)’s share price traded down 5.2% during mid-day trading on Friday . The company traded as low as $4.53 and last traded at $4.55. 922,414 shares changed hands during mid-day trading, a decline of 39% from the average session volume of 1,501,885 shares. The stock had previously closed at $4.80.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Needham & Company LLC reissued a “buy” rating and issued a $9.00 price target on shares of Autolus Therapeutics in a report on Friday, April 12th. Truist Financial raised their target price on shares of Autolus Therapeutics from $10.00 to $11.00 and gave the company a “buy” rating in a research note on Tuesday, April 9th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $8.16.

Autolus Therapeutics Price Performance

The business’s 50 day moving average is $5.93 and its two-hundred day moving average is $5.08. The firm has a market capitalization of $1.19 billion, a PE ratio of -3.84 and a beta of 1.90.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings results on Thursday, March 14th. The company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.18). Analysts expect that Autolus Therapeutics plc will post -0.71 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Perpetual Ltd grew its position in Autolus Therapeutics by 8.2% during the first quarter. Perpetual Ltd now owns 2,234,515 shares of the company’s stock valued at $14,256,000 after acquiring an additional 169,784 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in Autolus Therapeutics by 97.1% in the fourth quarter. Goldman Sachs Group Inc. now owns 131,731 shares of the company’s stock valued at $848,000 after acquiring an additional 64,910 shares in the last quarter. Perceptive Advisors LLC bought a new stake in Autolus Therapeutics in the fourth quarter valued at $11,793,000. Sierra Summit Advisors LLC bought a new stake in Autolus Therapeutics in the fourth quarter valued at $275,000. Finally, Price T Rowe Associates Inc. MD bought a new stake in Autolus Therapeutics in the fourth quarter valued at $19,328,000. 72.83% of the stock is currently owned by institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.